Cat. No.: HY-B0279

Ramipril

Name: Ramipril
Brand: MedChemExpress
SKU: HY-B0279
Price: 40.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: HOE-498)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Ramipril (HOE-498) is an orally active angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, and it is metabolized in vivo to the active metabolite Ramiprilat (HY-A0115). Ramipril has antioxidant, vasoprotective, and anti-atherosclerotic effects. Ramipril reduces the degradation of angiotensin II and bradykinin, downregulates TGF-beta/CTGF/fibronectin/α-SMA, and inhibits pancreatic/cardiac fibrosis. Ramipril improves glucose tolerance and insulin secretion, and reduces weight gain/appetite. Ramipril sensitizes mast cells, enhances FcεRI histamine release/degranulation, aggravates IgE allergic reactions, and downregulates the bradykinin receptor. Ramipril improves vascular endothelial relaxation function in spontaneously hypertensive rats. Ramipril alleviates Oxaliplatin (HY-17371)-induced acute hyperalgesia in mice. Ramipril can be used in research related to diseases such as type 2 diabetes, rheumatoid arthritis, allergy, and hypertension.

For research use only. We do not sell to patients.

Purity : 99.39%
CAS No.: 87333-19-5
Formula: C₂₃H₃₂N₂O₅
Molecular Weight:416.51

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ramipril Chemical Structure

CAS No.: 87333-19-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[3]^[1]

Bradykinin B1 Receptor (B1R)

ACE

All Bradykinin Receptor Isoforms :

All TGF-beta/Smad Isoforms :

Smad1
Smad3

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	392 μM Compound: Ramipril	Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 23777825]
HEK293	IC₅₀	414 μM Compound: Ramipril	Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 23777825]

In Vitro

Oxidative StressCardiovascular Regulation

Oxidative Stress

Cardiovascular Regulation

Ramipril (Ram) (10 μM; 48 h) eliminates HNE-induced reduction of mNADP-ICDH activity and HNE-induced increases in HNE/mNADP-ICDH adducts, type I collagen, and CTGF expression in isolated adult rat cardiomyocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Carbohydrate MetabolismCytokines & ChemokinesCardiovascular RegulationRegulation of Cardiac Pump FunctionLipid Inflammatory MediatorsOxidative StressImmune Tolerance & ImmunosuppressionInnate ImmunityOthers

Carbohydrate Metabolism

Cytokines & Chemokines

Ramipril (RAMI) (1-5 mg/kg; drinking water administration; 24 weeks) inhibits islet fibrosis, reduces α-SMA and TGF-β pathway markers, and improves glucose tolerance and insulin secretion index in OLETF type 2 diabetic rats; it reduces body weight gain and islet fibrosis, and improves glucose/insulin parameters in non-diabetic LETO rats^[1].

Cardiovascular Regulation

Regulation of Cardiac Pump Function

Ramipril (1 mg/kg; oral; daily; 12 weeks) chronically normalizes blood pressure and prevents cardiac hypertrophy in spontaneously hypertensive rats; it slightly reduces blood pressure and decreases body weight and heart weight in normotensive Wistar-Kyoto rats^[4].

Cytokines & Chemokines

Lipid Inflammatory Mediators

Oxidative Stress

Cardiovascular Regulation

Immune Tolerance & Immunosuppression

Ramipril (Ram) (10 mg/kg/day; intragastric administration; once daily; day 1 to day 28) attenuates arthritis severity, systemic and cardiac oxidative stress, and cardiac fibrosis in adjuvant-induced arthritis rats^[2].

Innate Immunity

Ramipril (approximately 1.5 mg/kg/day; oral administration via drinking water; daily; 12 weeks) attenuates radiation-induced damage to neural progenitor cell proliferation and neuronal differentiation in the rat dentate gyrus after 10 Gy whole-brain irradiation, shows no protective effect under 15 Gy irradiation, and simultaneously reduces the basal neurogenesis rate in the SGZ region of non-irradiated control rats^[6].

Innate Immunity

Lipid Inflammatory Mediators

Ramipril (R) (2.5 mg/kg; oral administration in drinking water; 14 days) alone slightly aggravates passive systemic anaphylaxis in female BALB/c mice, and its combination with Metoprolol (HY-17503) produces a more pronounced enhancing effect, accompanied by increased serum MC mediator release^[3].

Others

Ramipril (Ram) (3 mg/kg/day; intraperitoneal injection; daily; 10 days) improves the recovery of cold sensitivity and alleviates tactile allodynia in Oxaliplatin (HY-17371)-induced peripheral neuropathy in Swiss mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

OLETF (Otsuka Long-Evans Tokushima fatty; male; 20 weeks old; 400-450 g)
LETO (Long-Evans Tokushima Otsuka; 350-400 g)
^[1]
Dosage:

5 mg/kg; 1 mg/kg
Administration:

drinking water; 24 weeks
Result:

Inhibited islet fibrosis, reduced α-SMA and TGF-β pathway markers, and improved glucose tolerance and insulin secretion index in OLETF type 2 diabetic rats; it reduced body weight gain and islet fibrosis, and improves glucose/insulin parameters in non-diabetic LETO rats.

Animal Model:

Lewis (female, 220-240 g)^[2]
Dosage:

10 mg/kg/day
Administration:

oral gavage; once daily; day 1 through day 28
Result:

Decreased serum TNFα and PGE2 levels by approximately 2.6‑fold relative to AIA rats.
Inhibited the elevation of paw swelling and arthritis score.
Diminished HNE/protein adduct accumulation in serum and left‑ventricular (LV) tissues.
Reversed AIA‑provoked changes in cardiac mNADP‑ICDH activity and HNE/mNADP‑ICDH adduct amounts.
Restored cardiac NADPH and GSH substance pools.
Suppressed the up‑regulation of AT1R protein and mRNA within LV tissues.
Lowered cardiac collagen content to 1.9 % of the total surface area.

Animal Model:

BALB/c (female, 10-12 weeks old, wild-type)^[3]
Dosage:

2.5 mg/kg
Administration:

p.o. in drinking water; for 14 days
Result:

Showed slight enhancement of hypothermia (-0.75 °C).
Produced an additional 2.22 °C drop in core body temperature after Ramipril combined with Metoprolol treatment.
Induced obvious elevations of serum histamine, serotonin, LTC4 and PGD2 levels by ramipril combined with metoprolol.
Caused a mild reduction of mMCP‑1 level.

Animal Model:

Swiss (male, 6-7 weeks old, 25-30 g)^[5]
Dosage:

3 mg/kg/day
Administration:

i.p.; daily for 10 days; starting 1 day before first oxaliplatin injection
Result:

Tended to improve tactile sensitivity in oxaliplatin-administered mice at D3 and significantly restored normal tactile sensitivity at D5.
Significantly improved cold sensitivity on D1 in oxaliplatin-administered mice and restored normal cold sensitivity on D3.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 87333-19-5
Unlabeled CAS 87333-19-5
Appearance Solid
Molecular Weight 416.51
Formula C₂₃H₃₂N₂O₅
Color White to off-white
SMILES

O=C([C@@H]1C[C@@](CCC2)([H])[C@@]2([H])N1C([C@@H](N[C@H](C(OCC)=O)CCC3=CC=CC=C3)C)=O)O
Synonyms

HOE-498
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Pulm Pharmacol Ther

The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension. [Abstract]

2021 Oct:70:102072. PMID: 34428599

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (240.09 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (2.40 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4009 mL

12.0045 mL

24.0090 mL

5 mM

0.4802 mL

2.4009 mL

4.8018 mL

10 mM

0.2401 mL

1.2005 mL

2.4009 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.25 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3.25 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3.25 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 20 mg/mL (48.02 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (306 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ko SH, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochemical and biophysical research communications. 2004 Mar 26;316(1):114-22.

[2]. Shi Q, et al. Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis. Arthritis research & therapy. 2012 Oct 18;14(5):R223.

[3]. Nassiri M, et al. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. The Journal of allergy and clinical immunology. 2015 Feb;135(2):491-9.

[4]. Hutri-Kähönen N, et al. Ramipril therapy improves arterial dilation in experimental hypertension. Cardiovascular research. 1997 Jan;33(1):188-95.

[5]. Bouchenaki H, et al. Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice. Frontiers in pharmacology. 2021;12:712442.

[6]. Jenrow KA, et al. Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus. Radiat Oncol. 2010 Feb 1;5:6.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.4009 mL	12.0045 mL	24.0090 mL	60.0226 mL
DMSO	5 mM	0.4802 mL	2.4009 mL	4.8018 mL	12.0045 mL
	10 mM	0.2401 mL	1.2005 mL	2.4009 mL	6.0023 mL
	15 mM	0.1601 mL	0.8003 mL	1.6006 mL	4.0015 mL
	20 mM	0.1200 mL	0.6002 mL	1.2005 mL	3.0011 mL
	25 mM	0.0960 mL	0.4802 mL	0.9604 mL	2.4009 mL
	30 mM	0.0800 mL	0.4002 mL	0.8003 mL	2.0008 mL
	40 mM	0.0600 mL	0.3001 mL	0.6002 mL	1.5006 mL
	50 mM	0.0480 mL	0.2401 mL	0.4802 mL	1.2005 mL
	60 mM	0.0400 mL	0.2001 mL	0.4002 mL	1.0004 mL
	80 mM	0.0300 mL	0.1501 mL	0.3001 mL	0.7503 mL
	100 mM	0.0240 mL	0.1200 mL	0.2401 mL	0.6002 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ramipril

Publications Citing Use of MedChemExpress (MCE) Ramipril

All Bradykinin Receptor Isoforms

All TGF-beta/Smad Isoforms